Sermorelin Acetate

Specification

Mechanism of action

Sermorelin matches the biologically active amino-terminal portion of growth hormone releasing hormone (GHRH) and covers positions 1 to 29 with an amidated C-terminal group. At the pituitary GHRH receptor (GHRHR) the peptide starts G protein-coupled signal transduction: adenylyl cyclase is activated, the cAMP level rises, and the somatotropic axis is stimulated in cell and tissue models. Compared with extended GHRH analogues such as CJC-1295, Sermorelin remains the unmodified 1-29 fragment without albumin binding or DAC extension, which suits classical binding and release assays at native GHRH receptors. Laboratories that buy Sermorelin take the GHRH fragment 1-29 at 5 mg per vial.

Reconstitution and handling

The lyophilizate is reconstituted in the laboratory with a suitable sterile solvent. The solvent is added slowly along the vessel wall, and the preparation is mixed gently until the powder has dissolved completely. The resulting solution is transferred promptly into the planned assays, because dissolved peptide responds more readily to ambient conditions. Until use, the laboratory keeps the reagent out of direct light. Volume and final concentration are not part of this description; both are set in the respective protocol.

In vitro research

In in vitro research, Sermorelin serves as a reference ligand for competitive binding studies at the GHRH receptor and for cAMP reporter assays in somatotroph cell lines. Pharmacokinetic work on GHRH(1-29)-NH2 supplies reference frames for half-life and clearance in defined model systems. Combined with GHRP analogues such as Ipamorelin, co-stimulation experiments characterize the synergistic release of growth hormone at the cellular level. The uniform 5 mg strength per vial supports planning of dilution series and parallel measurement series across all ten vials in a box.

Quality and analytics

Each batch of Sermorelin acetate is tested by HPLC for purity; the content is ≥99 %. An identity check also confirms the 29-amino-acid backbone and the amidated C-terminal structure of the GHRH(1-29) fragment. Results are documented per batch. This characterization gives a reliable basis for reproducible receptor assays and for comparing measurement series.

Kit labeling

The ten vials in the box are unlabeled; substance name, strength, and batch reference appear on the outer kit packaging. The product image shows an example kit and may be reused for different strengths. The selected variant listing in the shop is authoritative for contents and dose.

Available amounts per vial: 5 mg, 10 mg. Box of 10 vials.